Replidyne cuts jobs, stops antibiotic program

Replidyne has cut about a third of its workforce and dumped one of its development programs in a restructuring. The company announced that most of the cuts were in administration, clinical, regulatory, and commercial operations while it was suspending work on a topical antibiotic, REP8839. A late-stage trial for faropenem in acute exacerbation of chronic bronchitis is continuing. Replidyne was a 2006 Fierce 15 company.

- check out this release
- here's the AFX report on the restructuring

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.